Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An S752D activation loop mutation dynamically primes Muscle-Specific Kinase for activation.

The Biochemical journal·2026

Same author

Lipids regulate epidermal growth factor receptor activation by its ligands.

Biochemical Society transactions·2026

Same author

The role of kinase domain dimerization in EGFR activation.

Structure (London, England : 1993)·2025

Same author

A comparative study of back pain, task-load and presenteeism in nursing homes.

Disability and rehabilitation. Assistive technology·2025

Same author

Reverse engineering of Onivyde® - Irinotecan liposome injection.

International journal of pharmaceutics·2024

Same author

Allosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling.

eLife·2024

Same journal

Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

Cancer discovery·2026

Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026

Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026

Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026

Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026

Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 22, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Occupy EGFR.

Jin H Park¹, Mark A Lemmon

¹Department of Biochemistry and Biophysics and Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19194-6059, USA.

Cancer Discovery

|May 17, 2012

Summary

This summary is machine-generated.

Erlotinib and gefitinib are ineffective against glioblastoma EGFR variants because they poorly inhibit the activated receptor. New EGFR inhibitors targeting different conformations show promise for glioblastoma treatment.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Epidermal growth factor receptor (EGFR) inhibitors like erlotinib and gefitinib are effective against non-small cell lung cancer with specific mutations.
However, these drugs show limited efficacy against EGFR variants found in glioblastoma, a type of brain cancer.

Purpose of the Study:

To investigate why erlotinib and gefitinib are ineffective against glioblastoma-derived EGFR mutants.
To identify alternative EGFR inhibitors that are more effective for glioblastoma treatment.

Main Methods:

Analysis of binding-site occupancy of erlotinib and gefitinib against glioblastoma-derived EGFR mutants.
Evaluation of the efficacy of other EGFR inhibitors targeting distinct receptor conformations in glioblastoma models.

Main Results:

Erlotinib and gefitinib exhibit limited binding-site occupancy and fail to inhibit activated glioblastoma-derived EGFR mutants.
EGFR inhibitors targeting different receptor conformations demonstrate greater efficacy in glioblastoma treatment.

Conclusions:

Drug selectivity varies significantly across different EGFR mutations.
Binding-site occupancy analysis can serve as a predictive biomarker for EGFR inhibitor efficacy in glioblastoma.